Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Federico

Showing results (91-100 of 271) with videos related to

Pageof 28
Sort By:
Annals of Hematology|September 18, 2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Andrea Ferrario, Francesco Merli, Stefano Luminari, et al.
Leukemia Research|February 12, 2013
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasAlessia Bari, Tamar Tadmor, Stefano Sacchi, et al.
British Journal of Haematology|July 30, 2013
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysisSamantha Pozzi, Luigi Marcheselli, Alessia Bari, et al.
British Journal of Haematology|May 2, 2022
End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphomaJesse G Dixon, Natalie Dimier, Tina Nielsen, et al.
Leukemia & Lymphoma|January 7, 2006
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei LinfomiNicola Di Renzo, Maura Brugiatelli, Antonella Montanini, et al.
Cancer|September 21, 2004
Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano LinformiFortunato Morabito, Andrea Gallamini, Caterina Stelitano, et al.
Haematologica|December 26, 2015
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II studyMassimo Federico, Stefano Luminari, Cinzia Pellegrini, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 3, 2023
Breast Cancer Prevention: The Key Role of Population Screening, Breast Self-Examination (BSE) and Technological Tools. Survey of Italian WomenLuana Conte, Giorgio De Nunzio, Roberto Lupo, et al.
Journal of Proteome Research|September 11, 2009
Identification of protein clusters predictive of response to chemotherapy in breast cancer patientsLaura Cortesi, Andrea Barchetti, Elisabetta De Matteis, et al.
Haematologica|September 2, 2004
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano LinfomiFrancesco Merli, Marilena Bertini, Stefano Luminari, et al.
Pageof 28

Showing results (91-100 of 271) with videos related to

Sort By:
Pageof 28
Annals of Hematology|September 18, 2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Andrea Ferrario, Francesco Merli, Stefano Luminari, et al.
Leukemia Research|February 12, 2013
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomasAlessia Bari, Tamar Tadmor, Stefano Sacchi, et al.
British Journal of Haematology|July 30, 2013
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysisSamantha Pozzi, Luigi Marcheselli, Alessia Bari, et al.
British Journal of Haematology|May 2, 2022
End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphomaJesse G Dixon, Natalie Dimier, Tina Nielsen, et al.
Leukemia & Lymphoma|January 7, 2006
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei LinfomiNicola Di Renzo, Maura Brugiatelli, Antonella Montanini, et al.
Cancer|September 21, 2004
Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano LinformiFortunato Morabito, Andrea Gallamini, Caterina Stelitano, et al.
Haematologica|December 26, 2015
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II studyMassimo Federico, Stefano Luminari, Cinzia Pellegrini, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 3, 2023
Breast Cancer Prevention: The Key Role of Population Screening, Breast Self-Examination (BSE) and Technological Tools. Survey of Italian WomenLuana Conte, Giorgio De Nunzio, Roberto Lupo, et al.
Journal of Proteome Research|September 11, 2009
Identification of protein clusters predictive of response to chemotherapy in breast cancer patientsLaura Cortesi, Andrea Barchetti, Elisabetta De Matteis, et al.
Haematologica|September 2, 2004
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano LinfomiFrancesco Merli, Marilena Bertini, Stefano Luminari, et al.
Pageof 28